Microbial Etiology of Ventilator-associated Pneumonia in COVID-19 Infected Patients

May 29, 2020 updated by: Poitiers University Hospital

Microbial Etiology of Ventilator-associated Pneumonia (VAP) in COVID-19 Infected Patients

National multicentric observational retrospective case-control study comparing the relative frequency of the various microorganisms responsible for VAP in patients infected or not by SARS-CoV-2 and their resistance to antibiotics.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

10000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 100 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All patients with microbiologically confirmed VAP with pulmonary samples collected from March 15 to April 15 in France.

Description

Inclusion Criteria:

  • All patients with microbiologically confirmed VAP with pulmonary samples collected from March 15 to April 15 in France.

Exclusion Criteria:

  • All patients with microbiologically confirmed VAP with pulmonary samples collected from March 15 to April 15 in France.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
COVID19-positive patients
Other: Bacterial species isolated
in the respiratory specimen
COVID19-negative patients
Other: Bacterial species isolated
in the respiratory specimen

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Prevalence of the microorganisms responsible for VAP among patients infected or not by the SARS-CoV-2
Time Frame: 1 month
1 month

Secondary Outcome Measures

Outcome Measure
Time Frame
Prevalence of multi-drug resistant bacteria responsible for VAP among patients infected or not by the SARS-CoV-2
Time Frame: 1 month
1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Poitiers University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

June 1, 2020

Primary Completion (Anticipated)

September 1, 2020

Study Completion (Anticipated)

December 1, 2020

Study Registration Dates

First Submitted

April 10, 2020

First Submitted That Met QC Criteria

April 10, 2020

First Posted (Actual)

April 14, 2020

Study Record Updates

Last Update Posted (Actual)

June 2, 2020

Last Update Submitted That Met QC Criteria

May 29, 2020

Last Verified

April 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PAVM COVID

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ventilator Associated Pneumonia

Clinical Trials on Bacterial species isolated

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe